Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-d activation

Diabetes

Volumn 62, Issue 3, 2013, Pages 762-774

  Li, Li ^a   Luo, Zhidan ^a   Yu, Hao ^a   Feng, Xiaoli ^a   Wang, Peijian ^a   Chen, Jian ^a   Pu, Yunfei ^a   Zhao, Yu ^a   He, Hongbo ^a   Zhong, Jian ^a   Liu, Daoyan ^a   Zhu, Zhiming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AS160 PROTEIN; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; TELMISARTAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; MOUSE; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TISSUE CULTURE; TRANSCRIPTION INITIATION; WILD TYPE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BIOLOGICAL TRANSPORT; CELL LINE; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIGANDS; MICE; MICE, KNOCKOUT; MUSCLE, SKELETAL; PHOSPHATIDYLINOSITOL 3-KINASE; PPAR GAMMA; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84874443818     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0570     Document Type: Article

References (47)

1. Taylor R. Insulin resistance and type 2 diabetes. Diabetes 2012;61:778-779
2. Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin-angiotensin system: A target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012;302:H1219-H1230
3. McMurray JJ, Holman RR, Haffner SM, et al.; NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-1490
4. Chai W, Wang W, Liu J, et al. Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use. Hypertension 2010;55:523-530
5. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76-81
6. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor g modulators with angiotensin receptor blocking activity. Diabetes 2005;54:3442-3452
7. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgammamodulating activity. Hypertension 2004;43:993-1002
8. Spiegelman BM. PPAR-g: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-514
9. Grimaldi B, Bellet MM, Katada S, et al. PER2 controls lipid metabolism by direct regulation of PPARg. Cell Metab 2010;12:509-520
10. Ehrenborg E, Krook A. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacol Rev 2009;61:373-393
11. Krämer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A. Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem 2007;282:19313-19320
12. Luquet S, Lopez-Soriano J, Holst D, et al. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J 2003;17:2299-2301
13. Gan Z, Burkart-Hartman EM, Han DH, et al. The nuclear receptor PPARb/d programs muscle glucose metabolism in cooperation with AMPK and MEF2. Genes Dev 2011;25:2619-2630
14. Schuler M, Ali F, Chambon C, et al. PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab 2006;4: 407-414
15. Lee CH, Olson P, Hevener A, et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 2006;103:3444-3449
16. Wang YX, Zhang CL, Yu RT, et al. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2004;2:e294
17. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 2004;10:481-483
18. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptordelta accelerates intestinal adenoma growth. Nat Med 2004;10:245-247
19. Brüning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998;2:559-569
20. Zhang LL, Yan Liu D, Ma LQ, et al. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res 2007;100:1063-1070
21. Ma S, Yu H, Zhao Z, et al. Activation of the cold-sensing TRPM8 channel triggers UCP1-dependent thermogenesis and prevents obesity. J Mol Cell Biol 2012;4:88-96
22. McClung JP, Roneker CA, Mu W, et al. Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci USA 2004;101:8852-8857
23. Merlin J, Evans BA, Csikasz RI, Bengtsson T, Summers RJ, Hutchinson DS. The M3-muscarinic acetylcholine receptor stimulates glucose uptake in L6 skeletal muscle cells by a CaMKK-AMPK-dependent mechanism. Cell Signal 2010;22:1104-1113
24. Wang X, Yu W, Nawaz A, Guan F, Sun S, Wang C. Palmitate induced insulin resistance by PKCtheta-dependent activation of mTOR/S6K pathway in C2C12 myotubes. Exp Clin Endocrinol Diabetes 2010;118:657-661
25. Yan ZC, Liu DY, Zhang LL, et al. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun 2007; 354:427-433
26. Levskaya A, Weiner OD, Lim WA, Voigt CA. Spatiotemporal control of cell signalling using a light-switchable protein interaction. Nature 2009;461: 997-1001
27. Yamamoto K, Ohishi M, Ho C, Kurtz TW, Rakugi H. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation. Hypertension 2009;54:1353-1359
28. Tagami T, Yamamoto H, Moriyama K, et al. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology 2009;150:862-870
29. Alkhateeb H, Chabowski A, Glatz JF, Gurd B, Luiken JJ, Bonen A. Restoring AS160 phosphorylation rescues skeletal muscle insulin resistance and fatty acid oxidation while not reducing intramuscular lipids. Am J Physiol Endocrinol Metab 2009;297:E1056-E1066
30. Leto D, Saltiel AR. Regulation of glucose transport by insulin: Traffic control of GLUT4. Nat Rev Mol Cell Biol 2012;13:383-396
31. Xie X, Gong Z, Mansuy-Aubert V, et al. C2 domain-containing phosphoprotein CDP138 regulates GLUT4 insertion into the plasma membrane. Cell Metab 2011;14:378-389
32. Yip MF, Ramm G, Larance M, et al. CaMKII-mediated phosphorylation of the myosin motor Myo1c is required for insulin-stimulated GLUT4 translocation in adipocytes. Cell Metab 2008;8:384-398
33. Mori Y, Tanaka T, Matsuura K, Yokoyama J, Utsunomiya K. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). Adv Ther 2011;28:698-706
34. de Luis DA, Conde R, González-Sagrado M, et al. Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients. Nutr Hosp 2010;25:275-279
35. Smith DH, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000;40:1380-1390
36. Washida K, Ihara M, Nishio K, et al. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator- activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. Stroke 2010;41:1798-1806
37. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 2006;48:51-57
38. He H, Yang D, Ma L, et al. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-deltadependent pathways. Hypertension 2010;55:869-879
39. Tikellis C, Cooper ME, Thomas MC. Role of the renin-angiotensin system in the endocrine pancreas: Implications for the development of diabetes. Int J Biochem Cell Biol 2006;38:737-751
40. Yuen CY, Wong WT, Tian XY, et al. Telmisartan inhibits vasoconstriction via PPARg-dependent expression and activation of endothelial nitric oxide synthase. Cardiovasc Res 2011;90:122-129
41. Brunham LR, Kruit JK, Pape TD, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007;13:340-347
42. Clemenz M, Frost N, Schupp M, et al. Liver-specific peroxisome proliferator-activated receptor a target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008;57: 1405-1413
43. Kang K, Reilly SM, Karabacak V, et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab 2008;7:485-495
44. Pang M, de la Monte SM, Longato L, et al. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol 2009;50:1192-1201
45. Jimenez R, Sanchez M, Zarzuelo MJ, et al. Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 kinase-Akt pathway. J Pharmacol Exp Ther 2010;332: 554-561
46. Pedchenko TV, Gonzalez AL, Wang D, DuBois RN, Massion PP. Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer. Am J Respir Cell Mol Biol 2008;39:689-696
47. Krämer DK, Al-Khalili L, Perrini S, et al. Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor d. Diabetes 2005;54:1157-1163